Abstract
Remoxipride, a D2-dopamine receptor antagonist, is well tolerated and completely absorbed after oral administration. Because of its extremely bitter taste, an oral palatable suspension was developed by using a taste-masking microencapsulation. The bioavailability of remoxipride was investigated in two studies in healthy volunteers after administration of a 100-mg dose in suspension. The first study used a capsule as reference, and the second study a plain solution. Taste assessment was carried out in the second study. The extent of bioavailability was the same when comparing the oral suspension to a capsule and to a plain solution. However, the rate of absorption is delayed, and Tmax was 3.0 hr after the suspension, 1.0 hr after the oral solution, and 1.6 hr after the capsule. The release rate in vitro from the suspension was determined by applying the USP-paddle method. By using numerical convolution and deconvolution, the release rates in vivo and in vitro were shown to be similar when using water with 0.5% sodium lauryl sulfate as dissolution liquid. The taste-masked oral suspension is suitable for full-scale production, with good control of the encapsulation process and of the preparation of a suspension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
L. Lindström, G. Besev, G. Stening, and E. Widerlöf. An open study of remoxipride, a benzamide derivation in schizophrenia. Psychopharmacology 86:241–243 (1985).
R. G. McCreadie, N. Todd, M. Livingstone, D. Eccleston, J. A. Watt, D. Tait, G. Crocket, M. J. Mitchell, and B. Hiutfeldt. A double blind study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psych. Scand. 78:49–56 (1988).
R. G. McCreadie, D. Morrison, D. Eccleston, R. G. Gall, J. Loudon, and M. J. Mitchell. An open multicentre study of the treatment of florid schizophrenia with remoxipride. Acta Psych. Scand. 72:139–143 (1985).
H. Chouinard. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J. Clin. Pharmacol. 7:159–164 (1987).
A. Lund Laursen and J. Gerlach. Antipsychotic effect of remoxipride a new substituted benzamide with selective antidopaminergic activity. Acta Psych. Scand. 73:17–21 (1986).
K.-G. Jostell and Y. D. Lapierre. Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. Acta. Psych. Scand. (in press).
M. Nicklasson, C. Graffner, L. Nilsson, M.-I. Nilsson, and A. Wahlén. Absorption properties of the new potential antipsychotic drug remoxipride after oral administration to healthy volunteers. Pharm. Ind. 47:986–990 (1985).
M. Nicklasson, C. Graffner, and M.-I. Nilsson. Assessment of in vivo dissolution by means of numerical deconvolution considering gastrointestinal availability. Int. J. Pharm. 40:165–171 (1987).
M. Grind, M.-I. Nilsson, L. Nilsson, G. Oxenstierna, G. Sedvall, and A. Wahlén. Remoxipride—a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy volunteers. Psychopharmacology 98:304–309 (1989).
L. Farde, M. Grind, M.-I. Nilsson, S. Ogenstad, and G. Sedvall. Remoxipride—a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers. Psychopharmacology 95:157–161 (1988).
P. Gibson, C. Q. Mountjoy, and R. L. G. Sutcliffe. Palatability of liquid major tranquilizers. Int. J. Ger. Psych. 6:235–238 (1991).
M.-Y. Fu Lu, S. Borodkin, L. Woodward, P. Li, C. Diesner, L. Hernandez, and M. Vadnere. A polymer carrier system for taste masking of macrolide antibiotics. Pharm. Res. 8:706–712 (1991).
S. P. Manek and V. S. Kamat. Evaluation of indion CRP 244 CRP 254 as sustained release and taste masking agents. Ind. J. Pharm. Sci. 43:209–212 (1981).
J. Sjövall, R. Sjöqvist, B. Huitfeldt, and H. Nyqvist. Correlation between the bioavailability of microencapsulated bacampicillin hydrochloride in suspension and in vitro microcapsule dissolution. J. Pharm. Sci. 73:141–145 (1984).
K. J. Mattsson, A. G. M. Nicklasson, and R. I. Sjöqvist. A liquid dosage form for oral administration of a pharmaceutically active substance. U.S. patent 5, 085, 868.
L. B. Nilsson. Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. J. Chromatogr. 526:139–150 (1990).
F. Langenbucher. Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability. Pharm. Ind. 44:1166–1172 (1982).
E. L. Lehmann. Nonparametrics: Statistical Methods Based on Ranks, Holden-Day, San Francisco, 1975.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sjöqvist, R., Graffner, C., Ekman, I. et al. In Vivo Validation of the Release Rate and Palatability of Remoxipride-Modified Release Suspension. Pharm Res 10, 1020–1026 (1993). https://doi.org/10.1023/A:1018966823600
Issue Date:
DOI: https://doi.org/10.1023/A:1018966823600